Customer Feedback for GS441524

Follow-up Protocol: Phased Monitoring of Viral Load and Organ Function

At Treatment Completion (Weeks 12/16/20): Complete the “Blood Test + Viral Detection” package, including:

- Complete Blood Count (CBC) to assess inflammation resolution

- Biochemical Panel (liver/kidney function, albumin-globulin ratio)

- FIPV RNA Detection (blood + feces) to screen for residual virus. Clinical cure is confirmed if the W/S ratio returns to ≥0.8 and FIPV RNA is negative.

1 month post-treatment: Re-test FIPV RNA (focusing on blood) to confirm no viral rebound. If the cat previously exhibited neurological symptoms, additional brain imaging (e.g., MRI) is required to rule out residual granulomas.

3-6 months post-treatment: Conduct comprehensive physical examination (including abdominal ultrasound to assess liver/spleen size normalization). If all parameters are normal, subsequent monitoring may follow standard feline intervals (annual check-ups) without frequent follow-ups.

Continue feeding high-protein food for 1-2 months post-recovery, then gradually transition to regular cat food to avoid gastrointestinal upset from sudden dietary changes. Avoid raw meat and eggs (to prevent Salmonella infection; immunity remains compromised for 1 year after FIP recovery).

Administer core vaccines (feline distemper, feline calicivirus, feline parvovirus) 1-2 months post-treatment. Do not administer FIP vaccines (no effective FIP vaccine currently exists). Test antibody levels before vaccination to ensure boosts are given only when immunity is insufficient, avoiding unnecessary immune system stimulation.

Recovered cats may gradually resume normal activities, but strenuous exercise (e.g., climbing heights, prolonged chasing) should be avoided. This is especially critical for cats with a history of pleural effusion, as full pulmonary function recovery typically takes 3-6 months.

The safety profile of GS-441524 has been extensively evaluated in both preclinical and clinical studies. In general, the compound is well-tolerated by cats and humans, with a low incidence of adverse effects. The most common side effects observed in cats treated with GS-441524 for FIP include mild gastrointestinal disturbances, such as vomiting and diarrhea, which are usually transient and resolve on their own.

In human studies, the safety of Remdesivir (which contains GS-441524 as its active metabolite) has been evaluated in clinical trials involving patients with COVID-19. The results showed that Remdesivir was generally well-tolerated, with the most common adverse effects being nausea, vomiting, and elevated liver enzymes. However, these side effects were usually mild to moderate in severity and did not require discontinuation of treatment.

It is important to note that the safety of GS-441524 has not been fully evaluated in all populations, particularly in pregnant women, children, and individuals with underlying medical conditions. Therefore, caution should be exercised when using GS-441524 in these vulnerable groups, and further research is needed to determine its safety and efficacy in these populations.